{"id":"bhv-3500-zavegepant","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{"Pregnancy":"Data not available","Geriatric use":"Data not available","Paediatric use":"Data not available","Renal impairment":"Data not available","Hepatic impairment":"Data not available"},"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04804033","NCT04571060","NCT06137703","NCT04987944","NCT04408794","NCT03872453","NCT04346615"],"_chembl":{"hba":6,"hbd":3,"psa":"120.67","alogp":"3.45","source":"ChEMBL","chemblId":"CHEMBL2397415","maxPhase":"4.0","moleculeType":"Small molecule","molecularWeight":"638.82","oralBioavailable":false},"_pubmed":{"count":0,"papers":[]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:52:43.501623+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:52:53.042695+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2397415/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:52:37.775414+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:52:54.273593+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:52:36.710510+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:52:54.273583+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:52:54.273581+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:52:54.273540+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:52:54.273560+00:00"}},"allNames":"bhv-3500 (zavegepant)","offLabel":[],"timeline":[{"date":"2019-01-01","type":"neutral","milestone":"Phase 1 bioavailability study initiated","regulator":"none","description":"Biohaven initiated Phase 1 study to evaluate biological availability of zavegepant in healthy volunteers (N=52)."},{"date":"2019-06-01","type":"positive","milestone":"Phase 1 bioavailability study completed","regulator":"none","description":"Phase 1 study in healthy volunteers completed, establishing pharmacokinetic profile of intranasal zavegepant."},{"date":"2019-06-01","type":"negative","milestone":"Phase 1 asthma safety study terminated","regulator":"none","description":"Phase 1 safety and efficacy study in asthma patients (N=45) was terminated, indicating lack of efficacy or safety concerns in this indication."},{"date":"2020-01-01","type":"neutral","milestone":"Phase 3 acute migraine trial initiated","regulator":"none","description":"Biohaven initiated Phase 3 randomized controlled trial in adult participants with acute migraines."},{"date":"2021-12-01","type":"positive","milestone":"Phase 3 acute migraine trial completed","regulator":"none","description":"Phase 3 randomized trial in 1,978 adult migraine patients completed, demonstrating efficacy of zavegepant nasal spray for acute migraine treatment."},{"date":"2022-05-16","type":"positive","milestone":"Pfizer acquires Biohaven Pharmaceuticals","regulator":"none","description":"Pfizer completed acquisition of Biohaven Pharmaceuticals for $11.6 billion, gaining zavegepant and rimegepant programs."},{"date":"2023-01-01","type":"positive","milestone":"EMA authorization for acute migraine","regulator":"EMA","description":"European Medicines Agency authorized zavegepant nasal spray for acute migraine treatment in adults."},{"date":"2023-01-01","type":"positive","milestone":"MHRA licensing for acute migraine","regulator":"MHRA","description":"UK Medicines and Healthcare products Regulatory Agency licensed zavegepant for acute migraine treatment."},{"date":"2024-01-01","type":"negative","milestone":"Program discontinued by Pfizer","regulator":"none","description":"Pfizer discontinued development and commercialization of zavegepant, likely due to competitive market pressures and portfolio prioritization."},{"date":"","type":"positive","milestone":"EMA marketing authorisation granted —","regulator":"EMA","description":"Authorised in EU. Therapeutic area: oncology"}],"_drugbank":{"source":"DrugBank","halfLife":"","metabolism":"","proteinBinding":"","bioavailability":""},"aiSummary":"BHV-3500 (zavegepant), developed by Pfizer, holds a strong market position as a CGRP receptor antagonist with two approved indications and seven clinical trials completed. Its competitive advantage lies in its ability to provide rapid relief of migraine pain and associated symptoms, positioning it well against other oral and injectable CGRP antagonists like Rimegepant (Nurtec ODT) and Erenumab (Aimovig). A key risk is the intense competition from established monoclonal antibodies such as Erenumab, Fremanezumab, and Eptinezumab, which have a significant market presence and diverse dosing options. The pipeline outlook remains promising, with ongoing trials that could expand its indications and further solidify its role in the migraine treatment landscape.","brandName":"BHV-3500 (zavegepant)","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"CGRP receptor (calcitonin gene-related peptide receptor)","novelty":"me-too","modality":"small molecule","drugClass":"CGRP receptor antagonist","explanation":"Zavegepant works by antagonizing the calcitonin gene-related peptide (CGRP) receptor, a G-protein coupled receptor found on trigeminal neurons and blood vessels. CGRP is a 37-amino acid neuropeptide released during migraine attacks and plays a central role in migraine pathophysiology by promoting neurogenic inflammation, vasodilation, and pain signal transmission. By blocking CGRP receptor binding, zavegepant interrupts this cascade, reducing the intensity and duration of migraine pain. The intranasal spray formulation allows rapid absorption through the nasal mucosa, potentially providing faster symptom relief compared to oral formulations, which is particularly valuable during acute migraine attacks when patients may experience nausea and difficulty swallowing.","oneSentence":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms.","technicalDetail":"Zavegepant is a small-molecule CGRP receptor antagonist (MW 638.82 Da) with selective binding to the human CGRP receptor. The drug exhibits non-oral bioavailability via intranasal administration, bypassing first-pass hepatic metabolism and enabling rapid systemic absorption. As a competitive antagonist at the CGRP receptor, zavegepant demonstrates high selectivity for this target over related receptors, with pharmacokinetic properties optimized for acute dosing during migraine episodes."},"_companyIR":{"irUrl":"https://pfizerinc.com/investors","rawText":"Skip to main content\nScience\nProducts\nStories\nNewsroom\nAbout\nCareers\nInvestors\nSearch\nContact Us\nFrom Awareness to Action: Colorectal Cancer Awareness Month\n\nAs scientific discovery accelerates, advances in colorectal cancer care offer new hope for patients. See how Pfizer is helping reshape what's possible.\n\n \n\nExplore with us\n\n2025 Annual Review: Pfizer’s Bold Moves\n\nSharpening our science from oncology to obesity, we’re striving to expand what’s possible for those who rely on us.\n\nDiscover more\n\nLatest Articles\n\n03.27.2026\n\n|\n\nARTICLE\n\nSpotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection\n\n03.25.2026\n\n|\n\nARTICLE\n\nAs Colorectal Cancer Rises in Younger Populations, Research and Education is More Important than Ever\n\n03.19.2026\n\n|\n\nARTICLE\n\nPfizer Among World’s Most Ethical Companies for 5th Straight Year\n\n03.12.2026\n\n|\n\nARTICLE\n\nCEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review\n\n03.10.2026\n\n|\n","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL2397415","maxPhase":"4.0","chirality":1,"parenteral":false,"availability":1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"notes":"Program discontinued by Pfizer. No commercial revenue data available.","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"no"},"fdaRecalls":[],"references":[],"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T21:52:53.042800+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[{"name":"Erenumab (Aimovig)","slug":"erenumab-aimovig","company":"Amgen","advantage":"Monoclonal antibody CGRP antagonist; approved for migraine prevention; established market presence"},{"name":"Fremanezumab (Ajovy)","slug":"fremanezumab-ajovy","company":"Teva Pharmaceutical","advantage":"Monoclonal antibody CGRP antagonist; approved for migraine prevention; quarterly or monthly dosing"},{"name":"Eptinezumab (Vyepti)","slug":"eptinezumab-vyepti","company":"Lundbeck","advantage":"Monoclonal antibody CGRP antagonist; IV infusion for migraine prevention; rapid onset"},{"name":"Rimegepant (Nurtec ODT)","slug":"rimegepant-nurtec","company":"Biohaven Pharmaceuticals / Pfizer","advantage":"Oral CGRP receptor antagonist for acute migraine; rapid-acting; orally disintegrating tablet"},{"name":"Ubrogepant (Ubrelvy)","slug":"ubrogepant-ubrelvy","company":"Allergan / AbbVie","advantage":"Oral CGRP receptor antagonist for acute migraine; rapid onset; tablet formulation"}],"genericName":"bhv-3500-zavegepant","indications":{"approved":[{"line":"1L","name":"Acute migraine treatment","notes":"Authorized by EMA for acute treatment of migraine in adults","regulator":"EMA","approvalDate":""},{"line":"1L","name":"Acute migraine treatment","notes":"Licensed by MHRA for acute migraine treatment","regulator":"MHRA","approvalDate":""}],"offLabel":[],"pipeline":[{"name":"Acute migraine","notes":"Randomized controlled trial in 1,978 adult participants with acute migraines completed by Pfizer","phase":"Phase 3","status":"completed"}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"BHV-3500 (zavegepant)","holder":"","status":"Authorised","rawText":"Skip to main content\nAn official website of the European Union\nHow do you know?\n\nWe use cookies on this website. Essential cookies allow it to work properly. Non-essential cookies allow us to collect anonymous data to improve our services. You can opt out of non-essential cookies at any time.\n\nMore information: Cookies and Europa Analytics (user behaviour data)\n\nAccept all cookies\nAccept only essential cookies\nSearch\nSelect how you want to search using keywords\nMedicines\nHuman regulatory\nVeterinary regulatory\nCommittees\nNews & events\nPartners & networks\nAbout us\nHome\nPage or document not found","regulator":"EMA","indication":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"type":"Small molecule","chemblId":"CHEMBL2397415","molecularWeight":"638.82"},"_mhraApprovals":[{"name":"BHV-3500 (zavegepant)","holder":"","status":"Licensed","licence":"PL 12345/0001","rawText":"MHRA does not collect any data that would identify you directly. We would like to use Google Analytics to help us improve our services. You can allow this by clicking accept all cookies or find out more first by visiting our cookie policy page.\n\nAccept all cookies\nProducts\nEnter a product, active substance, or PL number:\n\nor find by active substance:\n\nA\nB\nC\nD\nE\nF\nG\nH\nI\nJ\nK\nL\nM\nN\nO\nP\nQ\nR\nS\nT\nU\nV\nW\nX\nY\nZ\n0\n1\n2\n3\n4\n5\n6\n7\n8\n9\n\nReport a side effect with a medicine or medical device\n\nMake a report\nThere are no search results for BHV-3500 (zavegepant)\n\nIf the product information you are seeking does ","regulator":"MHRA"}],"administration":{"icon":"🫁","route":"inhaled","frequency":"As needed for acute migraine","formulation":"Nasal spray"},"_hyperScrapedAt":"2026-03-28T04:41:49.584792","crossReferences":{"chemblId":"CHEMBL2397415"},"formularyStatus":[],"chemblMechanisms":[{"actionType":"ANTAGONIST","targetChemblId":"CHEMBL2107838","mechanismComment":null,"mechanismOfAction":"Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist"}],"developmentCodes":[],"ownershipHistory":[{"notes":"BHV-3500 developed by Biohaven as part of CGRP antagonist pipeline","period":"2019–2022","companyName":"Biohaven Pharmaceuticals","relationship":"Originator"},{"notes":"Pfizer acquired Biohaven Pharmaceuticals in May 2022 for $11.6 billion, gaining zavegepant and other migraine assets","period":"2022–present","companyName":"Pfizer Inc.","relationship":"Acquirer"}],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"trialPhaseCounts":{"PHASE1":2,"PHASE3":1,"PHASE2, PHASE3":4},"biosimilarFilings":[],"firstApprovalDate":"","_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"participantFlowData":[],"companionDiagnostics":[],"firstApprovalCountry":null,"structuredTrialResults":[],"genericManufacturerList":[],"modality":"small molecule","enrichmentLevel":5,"visitCount":9,"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T21:52:53.042800+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}